Anti-HIV antibodies

Patent metadata

Field	Value
Publication number	US-12534516-B2
Application number	US-201917287188-A
Country	US
Kind code	B2
Filing date	Oct 21, 2019
Priority date	Oct 22, 2018
Publication date	Jan 27, 2026
Grant date	Jan 27, 2026

Abstract

Provided herein are anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS.

First claim

What is claimed is:

1 . A method of neutralizing a human immunodeficiency virus (HIV) comprising contacting the virus with a sufficient amount of an isolated monoclonal antibody that specifically binds to HIV envelope glycoprotein (Env) and comprises a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (CDR1), VH CDR2, and VH CDR3 and a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3, wherein
(a) the VH CDR1 comprises any one of the amino acid sequences of SEQ ID NOs: 1-18; (b) the VH CDR2 comprises any one of the amino acid sequences of SEQ ID NOs: 19-36; (c) the VH CDR3 comprises any one of the amino acid sequences of SEQ ID NOs: 37-54; (d) the VL CDR1 comprises any one of the amino acid sequences of SEQ ID NOs: 55-72; (e) the VL CDR2 comprises any one of the amino acid sequences of SEQ ID NOs: 73-90; and (f) the VL CDR3 comprises any one of the amino acid sequences of SEQ ID NOs: 91-108.

2 . A method for passively immunizing a subject comprising administering to the subject in need thereof an effective amount of a monoclonal antibody or an isolated polynucleotide encoding the antibody, wherein the antibody specifically binds to human immunodeficiency virus envelope glycoprotein (HIV Env) and comprises a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (CDR1), VH CDR2, and VH CDR3 and a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3, wherein
(a) the VH CDR1 comprises any one of the amino acid sequences of SEQ ID NOs: 1-18; (b) the VH CDR2 comprises any one of the amino acid sequences of SEQ ID NOs: 19-36; (c) the VH CDR3 comprises any one of the amino acid sequences of SEQ ID NOs: 37-54; (d) the VL CDR1 comprises any one of the amino acid sequences of SEQ ID NOs: 55-72; (e) the VL CDR2 comprises any one of the amino acid sequences of SEQ ID NOs: 73-90; and (f) the VL CDR3 comprises any one of the amino acid sequences of SEQ ID NOs: 91-108.

3 . A method of treating human immunodeficiency virus/acquired immunodeficiency syndrome comprising administering to a subject in need thereof a therapeutically sufficient amount of a monoclonal antibody or an isolated polynucleotide encoding the antibody, wherein the antibody specifically binds to human immunodeficiency virus envelope glycoprotein (HIV Env) and comprises a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (CDR1), VH CDR2, and VH CDR3 and a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3, wherein
(a) the VH CDR1 comprises any one of the amino acid sequences of SEQ ID NOs: 1-18; (b) the VH CDR2 comprises any one of the amino acid sequences of SEQ ID NOs: 19-36; (c) the VH CDR3 comprises any one of the amino acid sequences of SEQ ID NOs: 37-54; (d) the VL CDR1 comprises any one of the amino acid sequences of SEQ ID NOs: 55-72; (e) the VL CDR2 comprises any one of the amino acid sequences of SEQ ID NOs: 73-90; and (f) the VL CDR3 comprises any one of the amino acid sequences of SEQ ID NOs: 91-108.

4 . The method of claim 3 , further comprising administering at least one additional therapeutic agent.

5 . The method of claim 2 , wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprise the amino acid sequences of
(a) SEQ ID NOs: 1, 19, 37, 55, 73, and 91, respectively; (b) SEQ ID NOs: 2, 20, 38, 56, 74, and 92, respectively; (c) SEQ ID NOs: 3, 21, 39, 57, 75, and 93, respectively; (d) SEQ ID NOs: 4, 22, 40, 58, 76, and 94, respectively; (e) SEQ ID NOs: 5, 23, 41, 59, 77, and 95, respectively; (f) SEQ ID NOs: 6, 24, 42, 60, 78, and 96, respectively; (g) SEQ ID NOs: 7, 25, 43, 61, 79, and 97, respectively; (h) SEQ ID NOs: 8, 26, 44, 62, 80, and 98, respectively; (i) SEQ ID NOs: 9, 27, 45, 63, 81, and 99, respectively; (j) SEQ ID NOs: 10, 28, 46, 64, 82, and 100, respectively; (k) SEQ ID NOs: 11, 29, 47, 65, 83, and 101, respectively; (l) SEQ ID NOs: 12, 30, 48, 66, 84, and 102, respectively; (m) SEQ ID NOs: 13, 31, 49, 67, 85, and 103, respectively; (n) SEQ ID NOs: 14, 32, 50, 68, 86, and 104, respectively; (o) SEQ ID NOs: 15, 33, 51, 69, 87, and 105, respectively; (p) SEQ ID NOs: 16, 34, 52, 70, 88, and 106, respectively; (q) SEQ ID NOs: 17, 35, 53, 71, 89, and 107, respectively; or (r) SEQ ID NOs: 18, 36, 54, 72, 90, and 108, respectively.

6 . The method of claim 2 , wherein the VH comprises one or more of
(a) the amino acid sequences of SEQ ID NOs: 109-126 or 310-315 at Kabat positions H31-H37; (b) the amino acid sequences of SEQ ID NOs: 127-144 or 316-318 at Kabat positions H52-H56; and (c) the amino acid sequences of SEQ ID NOs: 145-162 at Kabat positions H61-H62; and wherein the VL comprises one or more of (d) the amino acid sequences of SEQ ID NOs: 163-180 or 319-324 at Kabat positions L26-L34; (e) the amino acid sequences of SEQ ID NOs: 181-198 or 325-334 at Kabat positions L49-L56; (f) the amino acid sequences of SEQ ID NOs: 199-216 or 335-339 at Kabat positions L67-L70; and (g) the amino acid sequences of SEQ ID NOs: 217-234 at Kabat positions L89-L97.

7 . The method of claim 2 , wherein
(a) the VH comprises an amino acid sequence that is at least 95% 90% identical to any one of SEQ ID NOs: 235-252; and b) the VL comprises an amino acid sequence that is at least 95% 90% identical to any one of SEQ ID NOs: 253-270.

8 . The method of claim 2 , wherein the VH and VL comprise the amino acid sequences of
(a) SEQ ID NOs: 235 and 253, respectively; (b) SEQ ID NOs: 236 and 254, respectively; (c) SEQ ID NOs: 237 and 255, respectively; (d) SEQ ID NOs: 238 and 256, respectively; (e) SEQ ID NOs: 239 and 257, respectively; (f) SEQ ID NOs: 240 and 258, respectively; (g) SEQ ID NOs: 241 and 259, respectively; (h) SEQ ID NOs: 242 and 260, respectively; (i) SEQ ID NOs: 243 and 261, respectively; (j) SEQ ID NOs: 244 and 262, respectively; (k) SEQ ID NOs: 245 and 263, respectively; (l) SEQ ID NOs: 246 and 264, respectively; (m) SEQ ID NOs: 247 and 265, respectively; (n) SEQ ID NOs: 248 and 266, respectively; (o) SEQ ID NOs: 249 and 267, respectively; (p) SEQ ID NOs: 250 and 268, respectively; (q) SEQ ID NOs: 251 and 269, respectively; or (r) SEQ ID NOs: 252 and 270, respectively.

9 . The method of claim 2 , wherein the antibody further comprises a heavy and/or light chain constant region.

10 . The method of claim 2 , wherein the antibody is a chimeric antibody, an antibody fragment, a bispecific antibody, or a trispecific antibody.

11 . The method of claim 3 , wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 comprise the amino acid sequences of
(a) SEQ ID NOs: 1, 19, 37, 55, 73, and 91, respectively; (b) SEQ ID NOs: 2, 20, 38, 56, 74, and 92, respectively; (c) SEQ ID NOs: 3, 21, 39, 57, 75, and 93, respectively; (d) SEQ ID NOs: 4, 22, 40, 58, 76, and 94, respectively; (e) SEQ ID NOs: 5, 23, 41, 59, 77, and 95, respectively; (f) SEQ ID NOs: 6, 24, 42, 60, 78, and 96, respectively; (g) SEQ ID NOs: 7, 25, 43, 61, 79, and 97, respectively; (h) SEQ ID NOs: 8, 26, 44, 62, 80, and 98, respectively; (i) SEQ ID NOs: 9, 27, 45, 63, 81, and 99, respectively; (j) SEQ ID NOs: 10, 28, 46, 64, 82, and 100, respectively; (k) SEQ ID NOs: 11, 29, 47, 65, 83, and 101, respectively; (l) SEQ ID NOs: 12, 30, 48, 66, 84, and 102, respectively; (m) SEQ ID NOs: 13, 31, 49, 67, 85, and 103, respectively; (n) SEQ ID NOs: 14, 32, 50, 68, 86, and 104, respectively; (o) SEQ ID NOs: 15, 33, 51, 69, 87, and 105, respectively; (p) SEQ ID NOs: 16, 34, 52, 70, 88, and 106, respectively; (q) SEQ ID NOs: 17, 35, 5

Assignees

• Int Aids Vaccine Initiative

Inventors

• Landais Elise
• Sok Devin

Classifications

• G01N2800/26

  Infectious diseases, e.g. generalised sepsis · CPC title

• G01N2333/162

  env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• G01N33/56988

  HIV or HTLV · CPC title